ASCO Stocks To Consider This Week

By Joe Gantoss:The American Society of Clinical Oncology (ASCO) 2012 annual meeting will take place June 01 - 05, 2012, at McCormick Place in Chicago, IL. This meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting - "Collaborating to Conquer Cancer."

By KLLJ Investments: With the final scheduling decision of Arena Pharmaceuticals' (ARNA) lead drug Belviq coming any day, I would like to address both the upcoming launch and why I believe that investors that have taken a bearish view of the equity are likely on the wrong side of the trade.

By Ed Liston: Two of the three major players in the treatment of obesity, VIVUS Inc. (VVUS) and Arena Pharmaceuticals Inc. (ARNA) released their financial results and provided an update on recent developments. The third player, Orexigen Therapeutics Inc.

By Bio Vantage:VIVUS Inc. (VVUS) and Arena Pharmaceutical (ARNA) are front runners in the development of weight-loss drugs. The rollercoaster rides for both stocks over the past two years demonstrate the volatility of small cap biotech stocks without commercial products. The FDA finally approved ARNA's Belviq (lorcaserin) on June 27, 2012.

ByPropThink:By Jake King

By Osman Gulseven:Obesity market is one of the juiciest markets at the moment. According to the center for disease control, almost 36% of Americans are obese. Additionally, the total cost of obesity related diseases goes well above $140 billion. These staggering numbers prompted the pharmaceutical companies to endeavor in this market.

By Paulo Santos:Tomorrow makes for an interesting set of circumstances that might make it worthy to buy Arena Pharmaceuticals (ARNA) today. Arena Pharmaceuticals has already received FDA approval for its main obesity drug, "Belviq".

By StockPandit: << Return to Part 2